Newsroom | 39361 results

TORONTO--(BUSINESS WIRE)--Muse today announced Deep Sleep Boost (DSB), a new sleep feature designed to help users sustain deeper, more stable slow-wave sleep. Powered by Muse S Athena, Deep Sleep Boost delivers targeted slow-wave sleep support using AI-driven neural signal models trained on large-scale EEG data. These models enable precise detection of slow-wave sleep and real-time timing of acoustic stimulation, addressing the brain’s most restorative sleep stage—closely linked to physical rec...

LONDON & BOSTON--(BUSINESS WIRE)--Convatec, a global medical products and technologies company focused on solutions for the management of chronic conditions, has been awarded two group purchasing agreements in the Enterostomal Therapy Products category with Premier, Inc., effective April 1, 2026: National Agreement: The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for enterostomal therapy products. AscenDrive...

FORT WORTH, Texas--(BUSINESS WIRE)--Novaria Group (“Novaria”), a portfolio company of Arcline Investment Management, today announced its acquisition of Plasma Ruggedized Solutions (“PRS”), a leading provider of high-reliability conformal coatings for sensitive electronics serving defense, medical, and advanced industrial applications. PRS specializes in parylene coating, potting, and encapsulation solutions that protect electronics operating in harsh and demanding environments where performance...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the United States launch of ReadyFix™, a remote fleet management solution designed to help healthcare systems support device uptime. ReadyFix will seamlessly integrate with GE HealthCare’s MAC VU360™ resting ECG workstations, which are designed to deliver high-quality ECG readings that help clinicians make faster, more confident cardiac care decisions. When paired with ReadyFix, healthcare systems can leverage real-time** da...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board...

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...

DURHAM, N.C.--(BUSINESS WIRE)--restor3d, a leader in 3D-printed, personalized orthopedic solutions, today announced the full commercial launch of the Ossera™ AFX Ankle Fusion Cage System, a comprehensive platform engineered to address complex ankle fusion cases and now available in both standard off-the-shelf and made-to-order configurations. Following a successful limited market release over the past several months, restor3d has expanded the Ossera™ AFX portfolio to include a standardized impl...

NEW YORK--(BUSINESS WIRE)--Universal Maritime Solutions (“Unimed” or “the Company”), a leading global provider of medical and compliance solutions to the maritime industry, today announced the acquisition of Regenboog Shipping Pharmacy, a Netherlands-based distributor of pharmaceutical products and medical devices serving the maritime sector. Unimed is backed by ZCG Private Equity, the private equity arm of Z Capital Group, LLC (“ZCG”), a privately held global firm. Based in Rotterdam, Regenboo...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has received FDA 510(k) clearance for eyonis® LCS, its AI/ML-powered computer-aided detection and...

ニューオーリンズ＆ヨクネアム（イスラエル）--(BUSINESS WIRE)--（ビジネスワイヤ） -- 能動血管内デバイスのリーディングカンパニーであるラピッド・メディカル™は、DISTALS多施設共同無作為化対照試験からの最新の結果を発表しました。この試験では、中等度血管閉塞（MVO）脳卒中において、TIGERTRIEVER™ 13が内科的治療と比較して、優れた脳組織再灌流と安全性プロファイルを実現できることが示されました。この結果は、2026年国際脳卒中会議（ISC）のメイン閉会セッションで発表されました。 トップライン結果では、TIGERTRIEVER™ 13を適用した群は、薬物療法群と比較して症候性頭蓋内出血（sICH）を伴わない再灌流成功率が3倍高く、86.3%対27.7%（p < 0.001）との結果となりました。特筆すべきは、TIGERTRIEVER 13を投与された無作為化治療群では、sICHイベントが報告されなかったことです。比較においては、静脈内血栓溶解療法のみで報告されたsICH発生率は、最近の試験では2～6%と高くなっています1,2,3。 DISTAL...